BioAlberta Announces New President & CEO And Vice President

BioAlberta Announces New President & CEO And Vice President

EDMONTON, Alberta--(BUSINESS WIRE)--The BioAlberta Board of Directors announced today that Mr. Paul Stinson has been appointed BioAlberta's new President and CEO. Mr. Stinson is expected to take up his duties on Monday, September 29, 2014.

Dr. David Cox and Mr. Rick Smith, Co-Chairs of BioAlberta stated, "The BioAlberta Board was unanimous in its decision to make this appointment and are excited to have someone of Mr. Stinson's calibre lead the Association. With Mr. Stinson's breadth and depth of knowledge and experience within the life sciences, coupled with his first- hand involvement in national and international governmental affairs, Paul was a natural choice for this position."

Prior to his appointment as President and CEO of BioAlberta, Paul has led a distinguished career including assignments in nine countries on four continents, in the public and private sectors. He has been a regional program manager for a Canadian government agency in Singapore, a country CEO for two multinational pharmaceutical companies in Zimbabwe and India, the president of a provincial biotechnology industry association and, most recently, an entrepreneur.

Paul established CAPRA International Inc. (Canada-Asia-Pacific Rim Alliances) in 1997 to promote commercial strategic alliances between North America and Asia. In 1999, he served as managing director of UBC's Centre for Molecular Medicine and Therapeutics. In January 2001, he was appointed Executive Director of BC Biotech, where he remained until December 2004. From there, Paul became the first Director General of the Human Proteome Organization at McGill in 2005

Since 2006, Paul has focused CAPRA's initiatives in Hong Kong, China, and Thailand. He served two years as Overseas Representative for the Hong Kong Science and Technology Park. In 2008-09, Paul was a Senior Advisor at The Balloch Group, Beijing and assisted Chinese companies to secure financing through TBG. Moving to Thailand in March 2011, Paul worked for Amata Corporation in Thailand and was an active member of the Thai Canada Chamber of Commerce. Paul is joining BioAlberta from Suzhou, China, which has an active life sciences cluster of companies.

Paul graduated from the University of Western Ontario, followed by MBA studies at IMD in Lausanne, Switzerland. Paul is the father of twin sons.

"I'm delighted to join BioAlberta at this important stage and look forward to becoming re-acquainted with many members who attended BioPartnering North America in Vancouver, which BioAlberta co-hosted." stated President and CEO, Paul Stinson.

The Board of Directors also announces that Ms. Judi Bahl, presently Acting President of the Association, is to be appointed Vice President, effective immediately. Judi will continue as Acting President until Mr. Stinson is able to commence his duties.

About BioAlberta

BioAlberta has been the central voice and organizing hub for the life sciences industry in Alberta since 1999 and actively driving the vision of:

It is a private, not-for-profit industry association representing more than 140 members of Alberta's steadily increasing life science industry's producers, users and supporters in the province. These member companies operate in the specialized sectors such as health biotechnology and pharmaceuticals; medical technology and devices; agricultural biotechnology; natural health products and nutraceuticals; environmental biotechnology; and, industrial biotechnology and bioprocessing.

BioAlberta activities are focused on advocacy, promotion and proactively facilitating the growth of Alberta's life sciences industry. The association provides attentive, proactive and timely services and programs to member organizations. Whether it is a cost savings of a purchasing program, a marketing campaign, a publication, an educational session, or an advocacy campaign, BioAlberta expands members' dollars and reach.

More information is available at www.bioalberta.com

Contacts

BioAlberta
Judi Bahl
Vice President, 780-425-3802
Cell: 780-906-1213
Fax: 780-409-9263 

Suggested Articles

Seven years after regaining the fibrosis drug it had licensed out to Stromedix, Biogen is pulling the plug on a phase 2 study.

Smaller biotechs are continuing their biopharma hiring spree as two startups nab some big names for their aspiring cancer drug research.

In a 7-2 vote, an FDA panel backed Aimmune’s peanut allergy treatment for approval. It desensitizes patients with increasing doses of peanut protein.